foretinib

Drug Overview

The medication known as foretinib is an advanced pharmaceutical agent designed to disrupt the growth and survival of cancer cells. It is a highly specialized “Smart Drug” that belongs to a class of medications called targeted therapies. Unlike traditional chemotherapy, which attacks all fast-growing cells, foretinib is engineered to find and block specific proteins that tumors use to thrive and spread.

Here are the key details about this agent:

• Generic Name: Foretinib (also known as GSK1363089 or XL880).
• US Brand Names: None. It is currently an investigational drug.
• Drug Class: Multikinase Inhibitor / Tyrosine Kinase Inhibitor (TKI).
• Route of Administration: Oral (taken by mouth as a tablet or capsule).
• FDA Approval Status: Currently investigational. It is not yet FDA-approved for standard public use, but it has been studied extensively in Phase 1 and Phase 2 clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand how foretinib works, it helps to think of a cancer cell as a machine that has several “power switches” stuck in the “ON” position. These switches tell the cell to grow uncontrollably and build its own blood supply. Foretinib acts like a master key that turns several of these switches “OFF” at the same time.

Blocking the Growth Signals

At the molecular level, foretinib is a multikinase inhibitor. It specifically targets and binds to two very important families of receptors on the surface of cells:

1. MET (Hepatocyte Growth Factor Receptor): Many tumors overproduce the MET protein. When this protein is active, it sends a strong signal for the cancer cell to multiply and move to other parts of the body (metastasis). Foretinib blocks the ATP-binding site of the MET receptor, stopping the signal before it starts.
2. VEGFR (Vascular Endothelial Growth Factor Receptor): Tumors need blood to survive. They send out signals to grow new blood vessels toward them. Foretinib blocks the VEGFR-2 receptor, which effectively starves the tumor by cutting off its food and oxygen supply. This process is called “anti-angiogenesis.”

Molecular Level Impact

By inhibiting both MET and VEGFR-2, foretinib creates a “double-blockade.” It stops the cancer from growing (anti-proliferative) and stops it from building blood vessels (anti-angiogenic). This dual action makes it much harder for the tumor to survive and adapt compared to drugs that only hit one target.

FDA Approved Clinical Indications

Because foretinib is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being used in approved clinical trials for the following purposes:

Oncological Uses (In Clinical Trials):

• Papillary Renal Cell Carcinoma (PRCC): A specific type of kidney cancer often driven by the MET protein.
• Hepatocellular Carcinoma (HCC): Primary liver cancer.
• Head and Neck Squamous Cell Carcinoma: Specifically for tumors that have spread.
• Gastric (Stomach) Cancer: Studied for tumors that show high MET activity.
• Breast Cancer: Investigated for advanced or metastatic cases.

Non-oncological Uses:

• There are currently no non-oncological uses for foretinib in clinical trials.

Dosage and Administration Protocols

Foretinib is administered as an oral medication. Because it is an investigational drug, the exact dose can vary depending on the specific clinical trial protocol.

Special Considerations

• Hepatic/Renal Insufficiency: Since the liver processes foretinib, patients with liver issues require very close monitoring. Dose adjustments are often necessary for patients with impaired liver or kidney function to prevent the drug from building up to toxic levels.

Clinical Efficacy and Research Results

Clinical research into foretinib between 2020 and 2025 has focused on its ability to help patients with specific genetic markers.

• Kidney Cancer Success: In trials focusing on Papillary Renal Cell Carcinoma, foretinib demonstrated a “Disease Control Rate” of approximately 70 percent. This means that in the majority of patients, the tumors either shrank or stopped growing for a period of time.
• Survival Data: While broad survival rates are still being gathered in larger trials, early data indicates that patients with MET mutations respond significantly better to foretinib than those without the mutation. In some Phase 2 trials, patients experienced a “Progression-Free Survival” (living without the cancer getting worse) of several months.
• MET-Driven Tumors: Research shows that foretinib is particularly effective at overcoming resistance to other treatments in gastric and lung cancers where the MET pathway has become overactive.

Safety Profile and Side Effects

As a targeted therapy, foretinib generally has different side effects than traditional chemotherapy. Most side effects are related to the drug’s impact on blood pressure and the digestive system.

Common Side Effects (>10%):

• Hypertension: High blood pressure is very common because the drug affects blood vessels.
• Fatigue: A general sense of tiredness or lack of energy.
• Diarrhea: Mild to moderate digestive upset.
• Nausea: Feeling sick to the stomach.
• Decreased Appetite: A loss of interest in food.

Serious Adverse Events:

• Proteinuria: Too much protein in the urine, which can indicate kidney stress.
• Hand-Foot Syndrome: Redness, swelling, and pain on the palms of the hands and soles of the feet.
• Liver Enzyme Elevation: Changes in blood tests that show the liver is under stress.
• Bleeding Events: Because the drug affects blood vessel growth, there is a small risk of internal bleeding.

Black Box Warning: There is no FDA Black Box Warning for this investigational agent at this time.

Management Strategies:

• Blood Pressure Control: Most patients will need to take blood pressure medication while on foretinib.
• Skin Care: Using thick, fragrance-free moisturizers can help manage hand-foot syndrome.
• Monitoring: Regular blood and urine tests are mandatory to check liver and kidney health.

Research Areas

Foretinib is a major focus in Combination Immunotherapy research. Scientists are currently looking at how foretinib can be used alongside “Checkpoint Inhibitors” (drugs that help the immune system find cancer). The theory is that by blocking the MET and VEGFR proteins, foretinib makes the tumor environment more “inviting” for the body’s natural T-cells to attack.

In the field of Regenerative Medicine, researchers are studying the MET pathway to understand how tissues heal. Since MET is involved in cell movement, learning how foretinib blocks this in cancer helps scientists develop better ways to encourage healthy cell growth in non-cancerous diseases.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

• Genetic Testing: To see if the tumor has MET mutations (which makes the drug more likely to work).
• Baseline Blood Pressure: To ensure your heart is ready for the medication.
• Liver and Kidney Panel: Comprehensive blood and urine tests.

Precautions During Treatment:

• Sun Sensitivity: This drug may make your skin more sensitive to the sun. Wear sunscreen and protective clothing.
• Wound Healing: Targeted therapies like foretinib can slow down how fast your body heals after a cut or surgery. Always tell your doctor if you have a surgery planned.

“Do’s and Don’ts” List:

• DO check your blood pressure at home every day and keep a log for your doctor.
• DO stay hydrated to help your kidneys process the medication.
• DON’T take any new over-the-counter herbal supplements (like St. John’s Wort) without asking your doctor, as they can interfere with the drug.
• DON’T ignore sudden, sharp stomach pain or unusual bruising.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Foretinib is an investigational diagnostic and therapeutic agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.